BACKGROUND: Few studies have examined the relationship between cardiometabolic risk factors linked to metabolic syndrome and mortality among women with breast cancer. METHODS: We used the Women's Health Initiative to evaluate the relationship between cardiometabolic risk factors, including waist circumference (WC), blood pressure, cholesterol level, and presence of type 2 diabetes, and their relation with death from breast cancer, cardiovascular disease (CVD), and other causes among 8641 women with local or regional stage invasive breast cancer. Cox proportional hazards models were used to estimate hazard ratios, and 95% confidence intervals, adjusted for important predictors of survival. RESULTS: After a median of 11.3 years, there were 2181 total deaths, 619 (28.4%) of which were due to breast cancer. Most participants (55.7%) had at least 2 cardiometabolic risk factors, and 4.9% had 3 or 4. Having a larger number of risk factors was associated with higher risk of CVD and other-cause mortality (P trend < .001 for both), but not with breast cancer mortality (P trend 5 .86). Increased WC was associated with a higher risk of CVD (hazard ratio [HR], 1.28; 95% confidence interval [CI], 1.05-1.57) and other-cause mortality (HR, 1.32; 95% CI, 1.16-1.49) and only with a small and nonsignificant higher risk of breast cancer mortality (HR, 1.19; 95% CI, 0.93-1.52). The results did not differ in analyses stratified by race, hormone receptor status, or after an analysis of cases diagnosed within 5 years after baseline. CONCLUSIONS: Among women with early stage breast cancer, cardiometabolic risk factors are significantly associated with cardiovascular and other-cause mortality, but not breast cancer mortality.
INTRODUCTION
Metabolic syndrome (MetS) is a grouping of cardiometabolic risk factors linked to atherosclerotic heart disease, 1,2 diabetes mellitus, 3 and cancer. 4, 5 Different definitions of MetS have been proposed, and all include some measure of insulin resistance, dyslipidemia, and increased abdominal obesity. [6] [7] [8] [9] [10] The defining criteria for MetS have been harmonized by consensus from 3 international organizations and include 3 of the 5 following components: increased waist circumference (WC), elevated triglycerides, hypertension, elevated fasting glucose, and low high-density lipoprotein (HDL) cholesterol. 11 Several studies have demonstrated a relationship between cardiometabolic risk factors and postmenopausal breast cancer, including 2 meta-analyses of body mass index (BMI), 12, 13 a meta-analysis of other risk factors, 5 and studies evaluating MetS as a whole. [14] [15] [16] [17] Others have described the relationship between cardiometabolic risk factors and breast cancer mortality, [18] [19] [20] [21] [22] [23] [24] [25] including studies evaluating the effects of insulin resistance, 18, 19 body weight, 20, 21, 26 measures of central obesity, 27 or the joint impact of one or more risk factors. [22] [23] [24] [25] The increasing prevalence of MetS and evidence suggesting a relationship between cardiometabolic risk factors and breast cancer risk, potentially through a common shared pathway of altered insulin sensitivity and sex hormonal changes, highlights the importance of understanding the impact of these risk factors on outcomes after breast cancer. 28 The Women's Health Initiative (WHI) cohort provides an opportunity to explore the relationship between exposure to cardiometabolic risk factors and mortality after breast cancer.
PATIENTS AND METHODS

Study Population
The WHI consists of an observational cohort (N 5 93,676) and 3 clinical trials (N 5 68,132) including trials of hormone therapy (HT), dietary modification (DM), and Calcium 1 vitamin D. 29, 30 Eligible women were between the ages of 50 and 79 years, were postmenopausal, and had a predicted survival of at least 3 years. Participants were recruited from 40 clinical centers in the United States between October 1, 1993, and December 31, 1998, and were initially followed through March 2005. The participants subsequently provided consent for recontact for follow-up and release of medical records in two 5-year extension studies lasting through September 30, 2015 (https://www.whi.org/SitePages/WHI%20Home.aspx).
We included WHI participants who as of September 30, 2015, had developed pathologically confirmed invasive breast cancer after enrollment in either the observational cohort or a clinical trial (n 5 9651) and excluded women with a history of cancer (except nonmelanomatous skin cancer) before enrollment (n 5 782) and distant stage disease at diagnosis (n 5 228) resulting in an analytic cohort of 8641 (Supporting Fig. 1 ). Women with distant stage disease were excluded in order to establish a more homogenous study population with early stage breast cancer.
Cardiometabolic Risk Factors
We used information gathered on cardiometabolic risk factors collected prior to breast cancer diagnosis including WC and blood pressure (BP) measured during the WHI baseline clinic visit and history of diabetes and high cholesterol, which were self-reported. There was a median of 7.1 years (range, 0.003-20.6 years) between study entry and breast cancer diagnosis. High WC was defined as 88 cm, which is considered clinically significant, 31 and the suggested threshold for the definition of MetS for women in the United States. 11 High BP was defined as systolic BP >130 mm Hg and/or diastolic BP >85 mm Hg, as defined by others 11 or normal BP reading, and reported use of anti-hypertensive medications. Women were considered diabetic if they responded affirmatively to the question "Did a doctor ever say that you had sugar diabetes or high blood sugar when you were not pregnant?" or reported the use of any anti-diabetic medication at baseline. Women were considered to have high cholesterol if they responded affirmatively to the question "Has a doctor ever told you that you had high cholesterol requiring medication?" or reported at baseline use of cholesterol-lowering medication. Height and weight were measured at baseline using a standardized protocol as was information on self-reported medication use. BMI was computed as kg/m 2 .
Outcomes
Outcomes included mortality from breast cancer, cardiovascular disease (CVD), and other causes. Participants were followed for outcomes from breast cancer diagnosis until date of death or last contact before September 30, 2015. For those cases alive at last contact, 97% had at least 1 or more years of follow-up. CVD death included death due to definite coronary heart disease, cerebrovascular accident, pulmonary embolism, possible coronary heart disease, other CVD, and unknown CVD. Cause of death was determined by medical record review with central adjudication and linkage to the National Death Index. Agreement between local versus central adjudication was 94% for death due to any cancer and 73% for death due to CVD or other causes. 32 
Covariates
Standardized questionnaires were used at baseline to collect information on age, race/ethnicity, education, current health care provider, screening mammogram within the past 2 years, smoking, alcohol, recreational physical activity, postmenopausal HT, and history of another cancer (except non-melanomatous skin cancer) diagnosed after study enrollment and before breast cancer diagnosis. 29 Information on breast cancer prognostic and clinical factors included the Surveillance, Epidemiology and End Results (SEER) summary stage, size, lymph node involvement, grade, hormone receptor status (estrogen receptor [ER], progesterone receptor [PR] ) and HER2/neu overexpression, based on review of the pathology report using the SEER coding system. 32, 33 HER2/neu status was missing for 25% of the participants, and because this test was not performed commonly at baseline in the WHI, this variable was excluded from all of the analyses.
Data were collected on initial course of breast cancer therapy (surgery, radiation, and chemotherapy) on a subset of WHI participants (n 5 4094) who had Medicare A1B fee-for-service coverage at diagnosis, and these data were used in a subset analysis.
Statistical Analysis
The frequency distribution of demographics, cardiometabolic abnormalities, and tumor characteristics at diagnosis were summarized overall and by number of cardiometabolic abnormalities. The association between demographics, tumor characteristics, and presence of cardiometabolic abnormalities was assessed using either the Cochran-Armitage test for dichotomous variables, or the Mantel-Haenszel test for ordinal variables. Unknown categories and "other" race were excluded in any analysis of trend test.
The competing risks of death due to breast cancer, CVD, and other causes was first evaluated by plotting the cumulative incidence of death by the number of cardiometabolic abnormalities and compared using Gray's test. 34 Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between each of the 4 cardiometabolic abnormalities and death due to breast cancer, CVD, and other causes. The final models assessing individual cardiometabolic abnormalities were mutually adjusted for other cardiometabolic abnormalities, as well as age group, WHI trial, and other confounders that changed the HR estimate associated with cardiometabolic abnormalities (31) by at least 5%. For breast cancer mortality, the model was also adjusted for race/ethnicity, alcohol use, moderate to strenuous recreational physical activity, and BMI as a categorical variable. For CVD mortality the model was adjusted for alcohol use, moderate to strenuous recreational physical activity, and HT use. For other cause mortality, the model was adjusted for WHI trial and age group. Separate sensitivity analyses were conducted to determine whether the relationship between cardiometabolic abnormalities and breast cancer-specific, CVD, and other-cause mortality varied by race (white vs African American), obesity (BMI 30 kg/m 2 vs <30 kg/ m 2 ), ER status (1 vs 2), and after exclusion of participants in the intervention arms of the WHI hormone therapy and dietary modification trials. To account for the length of time from exposure at baseline to breast cancer diagnosis, a sensitivity analysis was conducted excluding women diagnosed 5 or more years from baseline. A separate subset analysis adjusting for first course of cancer treatment was performed for 4094 participants for whom cancer treatment information was available.
Descriptive analyses and proportional hazards models were completed using SAS version 9.4 (Cary, NC) and cumulative incidence plots were created using the R package "cmprsk". 35 To test the proportionality assumption for the Cox proportional hazards regression analysis, an interaction term between the log of time and the ordinal cardiometabolic abnormalities was added to each model, and the interaction terms were not statistically significant. Table 1 describes the demographic and clinical characteristics of breast cancer cases in the WHI stratified by number of cardiometabolic risk factors (none, 1-2, 3-4). Overall, mean age at WHI study enrollment was 62.9 (SD 6.9) years; the majority of participants were nonHispanic white (88%), educated beyond high school (82%) and had a health care provider (95%). The most common cardiometabolic risk factors were high WC (41%) and elevated BP (40%). History of high cholesterol and diabetes were observed in only 13% and 5% of patients, respectively. Approximately 64% of the women had at least 1 cardiometabolic risk factor, 28% had 2 or more risk factors, and 4.9% had 3 or more risk factors (data not shown). The majority of participants presented with local stage (77%), tumors <2 cm in size (73%), lymph node negative (78%), grade 1 or 2 (68%), and ER1 and/or PR1 (80%). Variables associated with a greater number of cardiometabolic risk factors included older age, less education, African American race, participation in a WHI clinical trial, having a current health care provider, having no mammogram in the past 2 years, being a nondrinker, no physical activity, no use of HT, higher BMI, and higher tumor grade. The mean BMI at enrollment was 28.2 kg/m 2 (standard deviation 5.9). After a median follow-up of 11.3 years after diagnosis, there were a total of 2181 deaths. Causes of death included 619 deaths due to breast cancer (28%), 459 deaths due to CVD (21%), 401 deaths due to other cancer deaths (18.4%), 196 deaths due to unknown causes (9.0%), and 506 deaths due to other causes (23.2%). The most prevalent other causes of death were dementia or Alzheimer's disease (n 5 114), chronic obstructive pulmonary disease (n 5 52), and pneumonia (n 5 46) ( Table 2 ). Figure 1 illustrates the unadjusted relationship between number of cardiometabolic risk factors and death due to breast cancer, CVD, or other causes. There was a higher death risk due to breast cancer associated with 1-2 or 3-4 risk factors compared to none (Fig. 1A) , although this association was not statistically significant (P 5 .44). A greater number of cardiometabolic risk factors was associated with a higher risk of death due to CVD (Fig. 1B) and death due to other causes (Fig. 1C) (P < .001 for both).
RESULTS
Original Article (Table 3) . Lastly, having 1-2 or 3-4 cardiometabolic risk factors versus no risk factors was significantly associated with an increased risk of CVD mortality (P trend < .001) and death due to other causes (P <.001).
Additional analyses tested whether the association between cardiometabolic risk factors and death due to breast cancer, CVD, and other causes differed by race, obesity, and ER status, and no significant effect modification was observed. Separate sensitivity analyses excluding women diagnosed with breast cancer 5 or more years after baseline and controlling for first course breast cancer treatment also did not change our results. 
DISCUSSION
Among postmenopausal women with early stage breast cancer in the WHI, a higher number of cardiometabolic risk factors was associated with death due to CVD and other causes, but was not significantly associated with death due to breast cancer. Only elevated WC was significantly associated with higher breast cancer mortality in unadjusted analysis; after adjustments for BMI and physical activity, this relationship was no longer significant. Additional sensitivity analyses evaluating time since diagnosis, receipt of treatment and exclusion of participants in the treatment arms of the DM and HT had no significant impact on the reported outcomes. African American participants and those with higher grade tumors had a greater number of cardiometabolic abnormalities. Clustering of cardiovascular risk factors recognized as MetS centers on the premise of insulin resistance that could influence breast cancer pathogenesis and progression through several proposed mechanisms. 28 Adipose tissue has an active role in endocrine signaling through leptin and other adipokines, which may initiate carcinogenesis and progression through their function as growth factors. 36 This process may be in part through activation of downstream signaling of the extracellular signal regulated kinase and signal reducer and activator of transcription 3 pathways by the long form of the leptin receptor. 37 Another mechanism could include the stimulation of aromatase activity and consequent increased synthesis of estrogen and transactivation of ER alpha in breast cancer cells, which could also influence progression of disease. 38 Risk associated with insulin resistance and chronic inflammation is increased by elevated levels of tumor necrosis factor alpha, interleukin-6, and plasminogen activator inhibitor 1, all of which are thought to promote angiogenesis and metastases. [39] [40] [41] Obesity and hyperglycemia are associated with hyperinsulinemia, resulting in a reduction of insulin-like growth factor binding proteins and an increase in free insulin-like growth factor 1, 42 which in turn creates changes in the cellular environment that promotes tumor development and progression via mitogenic, anti-apoptotic, pro-angiogenic, and induction of tumorrelated lymphangiogenesis. 43 Although the relationship between obesity, MetS, and breast cancer incidence has been largely established, 5, 12, 13, 17, 44 the relationship between cardiometabolic risk factors and breast cancer-specific mortality is less clear. [18] [19] [20] [21] [22] 45 The majority of previous studies assessed individual risk factors including diabetes, 18, 19, 45 and obesity 20, 21, 27 with only a few analyzing the relationship between groups of risk factors and breast cancer outcomes. [23] [24] [25] To our knowledge, the current analysis is the only study of breast cancer survivors that, in addition to assessment of breast cancer mortality, evaluated the relationship between cardiometabolic risk factors and death due to CVD. The unique features of the WHI include validated measurements of WC and BP, long follow-up, and medical record review with adjudication of causes of death with linkage to the National Death Index. 32 As shown by others, [46] [47] [48] our results suggest that following breast cancer death, CVD represents the leading competing cause of death in survivors of early breast cancer, and that the presence of multiple cardiometabolic risk factors markedly increases CVD-specific mortality.
In a previous cohort including participants sampled from a population-based registry and including a median of 6.3 years of follow-up, history of 3 or more MetS components was associated with worse breast cancer-specific (HR, 1.65; 95% CI, 1.02-2.69) and overall mortality (HR, 1.81; 95% CI, 1.44-2.29) among women with stage I and II disease. 24 Only weight was associated with higher 25 study, data from a single institution were stratified by triple-negative versus non-triple-negative status and after a median of 6.6 years, MetS was not associated with either relapse-free or overall survival. However, among women with triple-negative breast cancer, low HDL cholesterol was associated with both worse relapse-free survival (HR, 3.27; 95% CI, 2.08-5.11) and overall survival (HR, 3.07; 95% CI, 1.73-5.44).
Our results showing a relationship between WC and breast cancer mortality are similar to those of the Calip et al 24 study and are consistent with other reports. 20, 21, 26 Differences in strength of the associations may be in part due to different definitions and populations; for example, we used 88 cm as high WC, 11 whereas Calip et al used a BMI 27.7 kg/m 2 as a proxy for central obesity. We did not observe a significant relationship between history of hypercholesterolemia and breast cancer-specific mortality as reported by others 23, 25 ; however, this could be due to our use of self-reporting for history of high cholesterol or use of cholesterol-lowering medications as a proxy for hypercholesterolemia. In addition, self-reporting of high cholesterol is more likely representative of high low-density lipoprotein cholesterol as opposed to low HDL and elevated triglycerides that are the actual components of the MetS definition, and which were cited to have a significant influence on breast cancer outcomes in other studies. 23, 25 Our results demonstrating an association between cardiometabolic risk factors and death due to CVD are consistent with other studies in the general population. [49] [50] [51] [52] Our findings highlight the high prevalence of CVD risk factors in postmenopausal breast cancer survivors, with particularly high prevalence of overweight/ obesity and hypertension in the WHI. Because straightforward testing of WC and blood pressure can identify a subpopulation of breast cancer survivors at high risk of death due to CVD, these results focus attention on the need to address CVD risk factors in long-term survivors of breast cancer. Multimodality breast cancer treatment, including radiation and chemotherapy, may also act in concert with cardiometabolic risk factors and contribute to mortality. This has been recently highlighted in the American Society of Clinical Oncology guidelines for cancer survivors, 53 with the addition of guidelines that specifically address the breast cancer population. 54 Our study strengths include the large sample size and long follow-up, resulting in a robust number of outcomes, comprehensive data collection and physicianadjudicated cases and causes of death. Moreover, we examined the impact of each individual feature on mortality in addition to an ordinal analysis focused on number of features. Generally, mortality risk has been shown to increase with an increasing number of features; however, analysis of each feature individually has the potential to provide more information about the underlying biology of drivers of progression. Limitations include a reliance on indirect measures of laboratory variables and diabetes and high cholesterol defined by medical history and medication use. In a prior WHI analysis, Luo et al 55 demonstrated that medical record data on diabetes matched the reliability of Medicare data; however, the possibility for underdetection of diabetes and high cholesterol is an important limitation. In a comparison with other similar analyses, [23] [24] [25] the WHI cohort had comparable levels of obesity and high BP, but lower prevalence of diabetes and high cholesterol, suggesting that our results may be less generalizable and more relevant for populations similar to that of the WHI. Also, for 16% of our included deaths, the cause was classified as "unknown or other cause," which could have resulted in misclassification, especially if some of the unclassified deaths were actually related to breast cancer or CVD. It should be noted that in the WHI, agreement between local and central adjudication was 94% for death due to cancer and 73% for death due to CVD or other causes. 32 Lastly, we evaluated the presence of cardiometabolic risk factors at baseline, and information on these factors at time of diagnosis was not available. To address this concern, we conducted an analysis excluding women diagnosed 5 years after baseline, and our results were unchanged. The variability in the time between assessment of cardiovascular risk factors and breast cancer diagnosis (median 7.1 years, range 0.003-20.6 years) could have potentially weakened the associations between cardiovascular risk factors and breast cancer-specific mortality, in particular. It is also possible that the prevalence of the measured cardiovascular risk factors could have changed over time, which could have resulted in a stronger relationship with breast cancer mortality. However, we were not able to assess this with our dataset.
In conclusion, cardiometabolic risk factors are positively associated with higher mortality from CVD and other causes, but not with higher risk of death from breast cancer in postmenopausal women with breast cancer. Identifying and managing cardiometabolic risk factors should be the standard of care for all postmenopausal women diagnosed with breast cancer.
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